Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1906-1916

  Hernández, José M ^a   Bui, Matthew H T ^a   Han, Ken ryu ^a   Mukouyama, Hideki ^a   Freitas, Danielo G ^a   Nguyen, David ^a   Caliliw, Randy ^a   Shintaku, Peter I ^a   Paik, Sun H ^a   Tso, Cho Lea ^a   Figlin, Robert A ^a   Belldegrun, Arie S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; RNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FUSION GENE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY CANCER; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TUMOR GROWTH; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; ISOENZYMES; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MICE; MICE, SCID; MICE, TRANSGENIC; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 10744230408     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Schendel, D. J., and Gansbacher, B. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res., 53: 4020-4025, 1993.
2. Figlin, R. A. Renal cell carcinoma: management of advanced disease. J. Urol., 161: 381-386, 1999.
3. Brandle, D., Brasseur, F., Weynants, P., Boon, T., and Van den Eynde, B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med., 183: 2501-2508, 1996.
4. Gaugler, B., Brouwenstijn, N., Vantomme, V., Szikora, J. P., Van der Spek. C. W., Patard, J. J., Boon, T., Schrier, P., and Van den Eynde, B. J. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics, 44: 323-330, 1996.
5. Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., and Warnaar, S. O. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer, 38: 489-494, 1986.
6. Pastorek, J., Pastorekova, S., Callebaut, I., Mornon, J. P., Zelnik, V., Opavsky, R., Zatovicova, M., Liao, S., Portetelle, D., Stanbridge, E. J., Zavada, J., Burny, A., and Kettmann, R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene, 9: 2877-2888, 1994.
7. Wykoff, C. C., Beasley, N. J., Watson, P. H., Turner, K. J., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K. L., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., and Harris, A. L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res., 60: 7075-7083, 2000.
8. Ivanov, S., Liao, S. Y., Ivanova, A., Danilkovitch-Miagkova, A., Tarasova, N., Weirich, G., Merrill, M. J., Proescholdt, M. A., Oldfield, E. H., Lee, J., Zavada, J., Waheed, A., Sly, W., Lerman, M. I., and Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol., 158: 905-919, 2001.
9. Murakami, Y., Kanda, K., Tsuji, M., Kanayama, H., and Kagawa, S. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. B. J. U. International, 83: 743-747, 1999.
10. Uemura, H., Nakagawa, Y., Yoshida, K., Saga, S., Yoshikawa, K., Hirao, Y., and Oosterwijk, E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer, 81: 741-746, 1999.
11. Bui, M. H., Seligson, D., Han, K. R., Pantuck, A. J., Dorey, F. J., Huang, Y., Horvath, S., Leibovich, B. C., Chopra, S., Liao, S. Y., Stanbridge, E., Lerman, M. I., Palotie, A., Figlin, R. A., and Belldegrun, A. S. Carbonic anhydrase IX is an independent predictor of survival on advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin. Cancer Res., 9: 802-811, 2003.
12. Vissers, J. L., De Vries, I. J., Schreurs, M. W., Engelen, L. P., Oosterwijk, E., Figdor, C. G., and Adema, G. J. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res., 59: 5554-5559, 1999.
13. Grabmaier, K., Vissers, J. L., De Weijert, M. C., Oosterwijk Wakka, J. C., Van Bokhoven, A., Brakenhoff, R. H., Noessner, E., Mulders, P. A., Merkx, G., Figdor, C. G., Adema, G. J., and Oosterwijk, E. Molecular cloning and immunogenicity of renal cell carcinomaassociated antigen G250. Int. J. Cancer., 85: 865-870, 2000.
14. Rosenberg, S. A. Progress in human turnout immunology and immunotherapy. Nature (Lond.), 411: 380-384, 2001.
15. Tso, C. L., Zisman, A., Pantuck, A., Calilliw, R., Hernandez, J. M., Paik, S., Nguyen, D., Gitlitz, B., Shintaku, P. I., de Kernion, J., Figlin, R., and Belldegrun, A. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res., 61: 7925-7933, 2001.
16. Berns, A. J., Clift, S., Cohen, L. K., Donehower, R. C., Dranoff, G., Hauda, K. M., Jaffee, E. M., Lazenby, A. J., Levitsky, H. I., and Marshall, F. F. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without hGM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther., 6: 347-368, 1995.
17. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
18. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
19. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, R. M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176: 1693-1702, 1992.
20. Borrello, I., and Pardoll, D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev., 13: 185-193, 2002.
21. Yang, S., Vervaert, C. E., Burch, J., Jr., Grichnik, J., Seigler, H. F., and Darrow, T. L. Murine dendritic cells transfected with human gp100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Int. J. Cancer, 83: 532-540, 1999.
22. Butterfield, L. H., Jilani, S. M., Chakraborty, N. G., Bui, L. A., Ribas, A., Dissette, V. B., Lau, R., Gamradt, S. C., Glaspy, J. A., McBride, W. H., Mukherji, B., and Economou, J. S. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol., 161: 5607-5613, 1998.
23. Kaplan, J. M., Yu, Q., Piraino, S. T., Pennington, S. E., Shankara, S., Woodworth, L. A., and Roberts, B. L. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol., 163: 699-707, 1999.
24. Jager, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jager, D., Oesch, F., and Knuth, A. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer, 71: 142-147, 1997.
25. Hahn, Y. S., Hahn, C. S., and Braciale, T. J. Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation. Immunol. Cell Biol., 74: 394-400, 1996.
26. Wan, Y., Bramson, J., Pilon, A., Zhu, Q., and Gauldie, J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res., 60: 3247-3253, 2000.
27. Gabrilovich, D. I., Corak, J., Ciernik, I., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
28. Belldegrun, A., Tso, C. L., Sakata, T., Duckett, T., Brunda, M. J., Barsky, S. H., Chai, J., Kaboo, R., Lavey, R. S., McBride, W. H., and de Kernion, J. B. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J. Natl. Cancer Inst. (Bethesda), 85: 207-216, 1993.
29. Pastorekova, S., Zavadova, Z., Kostal, M., Babusikova, O., and Zavada, J. A novel quasi-viral agent. MaTu, is a two-component system. Virology, 187: 620-626, 1992.
30. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. A simplified method for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA, 95: 2509-2514, 1998.
31. Pantuck, A. J., Matherly, J., Zisman, A., Nguyen, D., Berger, F., Gambhir, S. S., Black, M. E., Belldegrun, A., and Wu, L. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum. Gene Ther., 13: 777-789, 2002.
32. Wu, L., Matherly, J., Smallwood, A., Adams, J. Y., Billick, E., Belldegrun, A., and Carey, M. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther., 8: 1416-1426, 2001.
33. Kasai, M., Iwamori, M., Nagai, Y., Okumura, K., and Tada, T. A glycolipid on the surface of mouse natural killer cells. Eur. J. Immunol.,10: 175-180
34. Metcalf, D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature (Lond.), 339: 27-30, 1989.
35. Clark, S. C., and Kamen, R. The human hematopoietic colonystimulating factors. Science (Wash. DC), 236: 1229-1237, 1987.
36. Hoss, A., Moarefi, I., Scheidtmann, K. H., Cisek, L. J., Corden, J. L., Dornreiter, I., Arthur, A. K., and Fanning. E. Altered phosphorylation pattern of simian virus 40 T antigen expressed in insect cells by using a baculovirus vector. J. Virol., 64: 4799-4807, 1990.
37. Kuroda, K., Veit, M., and Klenk, H. D. Retarded processing of influenza virus hemagglutinin in insect cells. Virology, 180: 159-165. 1991.
38. Poloso, N. J., Nagarajan, S., Mejia-Oneta, J. M., and Selvaraj, P. GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol. Immunol.38: 803-816, 2002.
39. Bendelac, A. Mouse NK+ T cells. Curr. Opin. Immunol., 7: 367-374, 1995.
40. Bix, M., and Locksley, R. M. Natural T cells. Cells that co-express NKRP-1 and TCR. J. Immunol., 155: 1020-1022, 1995.
41. Pardoll, D. M., and Topalian, S. L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol., 10: 588-594, 1998.
42. Toes, R. E., Ossendorp, F., Offringa, R., and Melief, C. J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med., 189: 753-756, 1999.
43. Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., and Schreiber, H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFNgamma. Proc. Natl. Acad. Sci. USA, 96: 8633-8638, 1999.
44. Yannelli, J. R., Hyatt, C., McConnell, S., Hines, K., Jacknin, L., Parker, L., Sanders, M., and Rosenberg, S. A. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer, 65: 413-421, 1996.
45. Vissers, J. L. M., de Vries, J. M., Engelen, L. P. H., Scharenborg, N. M., Molkenboer, J., Figdor, C. G., Oosterwijk, E., and Adema, G. J. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to CD4+ lymphocytes. Int. J. Cancer, 100: 441-444, 2002.
46. Li, Y., Newby, S. A., Johnston, J. V., Hellstrom, K. E., and Chen, L. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice. J. Immunol., 155: 5705-5710, 1995.
47. Nishijima, I., Nakahata, T., Watanabe, S., Tsuji, K., Tanaka, I., Hirabayashi, Y., Inoue, T., and Arai, K. Hematopoietic and lymphopoietic responses in human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor transgenic mice injected with human GMCSF. Blood, 90: 1031-1038, 1997.
48. Kraal, G., van Wilsem, E., and Breve, J. The phenotype of murine Langerhans cells from skin to lymph node. In Vivo, 7: 203-206, 1993.
49. Takashima, A., and Bergstresser, P. R. Cytokine-mediated communication by keratinocytes and Langerhans cells with dendritic epidermal T cells. Semin. Immunol., 8: 333-339, 1996.
50. De Creus, A., Van Beneden, K., Taghon, T., Stolz, F., Debacker, V., Plum, J., and Leclercq, G. Langerhans cells that have matured in vivo in the absence of T cells are fully capable of inducing a helper CD4 as well as a cytotoxic CD8 response. J. Immunol., 165: 645-653, 2000.
51. Jaffee, E. M., Thomas, M. C., Huang, A. Y., Hauda, K. M., Levitsky, H. I., and Pardoll, D. M. Enhanced immune priming with spatial distribution of paracrine cytokines vaccines. J. Immunother. Emphasis Tumor Immunol., 19: 176-183, 1996.
52. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., and Valone, F. H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol., 18: 3894-3903, 2000.
53. Wang, S. Y., Hsu, M. L., Su, C. Y., Lin, C. K., Hu, C. P., and Chang, C. M. In vivo stimulation of myelopoiesis in cyclophosphamidetreated mice by purified human GM-CSF. Zhonghua Yi Xue Za Zhi (Taipei), 48: 171-176, 1991.
54. Kaushansky, K., Lin, N., and Adamson, J. W. Interleukin 1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony-stimulating factors. Mechanism for the hematopoietic response to inflammation. J. Clin. Invest., 81: 92-97, 1988.